Physician profile
Mark A Knipfer
NPI 1982650172
$15,146.95
in general payments reported to CMS, 2019-2025
61 companies · $1,587 in 2025
The $1,587 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,614 · 2020: $1,613 · 2021: $2,548 · 2022: $3,127 · 2023: $1,785 · 2024: $1,873 · 2025: $1,587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,244 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,244.27 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,008.57 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,917.24 | 2020-2025 | |
| Novo Nordisk INC | $871.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $798.48 | 2019-2025 | Evenity, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $717.78 | 2019-2025 | |
| Pfizer INC. | $558.77 | 2019-2025 | |
| Amarin Pharma, INC. | $527.44 | 2019-2022 | |
| Lilly USA, LLC | $468.70 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $438.35 | 2019-2024 | Shingrix |
| Sanofi-Aventis U.S. LLC | $398.78 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $397.95 | 2021-2024 | Xifaxan |
| Astellas Pharma US INC | $394.73 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $394.70 | 2019-2025 | Spravato |
| Abbott Laboratories | $350.27 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Allergan, INC. | $314.97 | 2019-2020 |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $311.32 | 2019-2023 | Livalo, Seglentis |
| Bayer Healthcare Pharmaceuticals INC. | $307.85 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $301.30 | 2019-2023 | Trintellix |
| Esperion Therapeutics, INC. | $228.54 | 2020-2025 | Nexletol |
| Daiichi Sankyo INC. | $203.76 | 2019-2024 | Injectafer |
| Phathom Pharmaceuticals, INC. | $187.05 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $182.41 | 2019-2024 | Verquvo, Gardasil, Gardasil 9 |
| Teva Pharmaceuticals USA, INC. | $153.46 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $148.33 | 2021 | |
| Corium, LLC | $146.51 | 2022-2025 | Azstarys |
| Sumitomo Pharma America, INC. | $139.38 | 2023-2025 | Gemtesa |
| Corcept Therapeutics | $118.21 | 2024-2025 | Korlym |
| Antares Pharma, INC. | $117.96 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.33 | 2019-2025 | Jardiance |
| Abiomed | $97.24 | 2024-2025 | Impella |
| Baxter Healthcare | $84.29 | 2022 | |
| Alexion Pharmaceuticals, INC. | $80.24 | 2019-2020 | |
| Recor Medical INC | $50.32 | 2024 | Paradise Renal Denervation System |
| Inari Medical, INC. | $46.33 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Supernus Pharmaceuticals, INC. | $43.64 | 2019-2023 | Xyosted, Qelbree |
| Otsuka America Pharmaceutical, INC. | $42.19 | 2021-2024 | Rexulti |
| Arbor Pharmaceuticals, INC. | $41.50 | 2019-2020 | |
| Halozyme INC | $38.39 | 2023 | |
| Philips North America LLC | $31.42 | 2020 | |
| Genentech USA, INC. | $30.53 | 2019-2021 | |
| Agios Pharmaceuticals, INC. | $29.29 | 2023-2024 | Pyrukynd |
| Edwards Lifesciences Corporation | $27.13 | 2023-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Mannkind Corporation | $24.14 | 2019 | |
| Dexcom, INC. | $24.03 | 2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company Ltd. | $21.50 | 2022 | |
| Eisai INC. | $19.14 | 2025 | |
| Kyowa Kirin, INC. | $17.25 | 2024 | Crysvita |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.72 | 2024 | Caplyta |
| Upsher-Smith Laboratories LLC | $16.31 | 2022 | |
| Axsome Therapeutics, INC. | $15.67 | 2025 | Symbravo |
| Adlon Therapeutics L.P. | $15.52 | 2020 | |
| Idorsia Pharmaceuticals US INC | $14.91 | 2023 | Quviviq |
| Medtronic, INC. | $13.83 | 2021 | |
| Cranial Technologies, INC | $13.77 | 2023 | Doc Band |
| Intuity Medical INC | $13.56 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Exact Sciences Corporation | $13.25 | 2023 | Cologuard Collection Kit |
| Evofem Biosciences, INC. | $12.93 | 2021 | |
| Seqirus USA INC | $12.49 | 2022 | |
| Almatica Pharma LLC | $11.97 | 2021 | |
| Acadia Pharmaceuticals INC | $11.60 | 2021 | |
| Sanofi Pasteur INC. | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Knipfer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.